INTRODUCTION

Polycystic ovarian syndrome (PCOS) is an endocrine disorder with coexisting glucose metabolism abnormalities and reproductive dysfunction, with complex clinical symptoms as well as unclear etiology and pathogenesis. PCOS is clinically typified by androgen excess and chronic anovulation, manifested as menstrual disorders, hypomenorrhea, amenorrhea, obesity, infertility, hirsutism, acne, etc. At present, PCOS has mainly been associated with adrenal dysfunction, hypothalamic-pituitary dysfunction, insulin resistance, genetic factors, etc. In addition,
the disease is often complicated by metabolic abnormalities of other tissues, increasing the risk of cardiovascular diseases and endometrial cancer. As a result, the life, mental and physical healths of patients are severely affected. Currently, PCOS is generally clinical treated by taking oral contraceptives and insulin, but the therapeutic effects remain unsatisfactory. This study assessed the effects of metformin and clomiphene in combination with lifestyle adjustment on infertility in obese PCOS patients by observing the changes of reproductive endocrine and lipid metabolism.

METHODS

Baseline clinical data: A total of 101 infertile women with obese PCOS admitted to our hospital from July 2013 to July 2015 were selected, who were aged 22-34 years old, with a mean age of (27.8 ± 4.6). The durations of infertility ranged from 2 to 5 years, (3.08 ± 0.81) on average. All patients were randomly divided into an observation group (n=51) and a control group (n=50). In the observation group, the patients were aged 23-35 years old, with a mean age of (28.3 ± 5.1). The durations of infertility ranged from 2 to 6 years, (3.54 ± 0.79) years on average. In the control group, the patients were aged 24-36 years old, with a mean age of (27.8 ± 5.4). The durations of infertility ranged from 2 to 5 years, (3.12 ± 0.78) years on average. The two groups had similar duration of infertility and age (P>0.05). This study has been approved by the ethics committee of our hospital, and written consent has been obtained from all patients.

Diagnostic criteria: The criteria recommended by the European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine (ESHRE/ASRM) at the Rotterdam Conference in 2003 were used:3
1. Sporadic ovulation or anovulation
2. Clinical manifestations of hyperandrogenism and/or hyperandrogenemia
3. Ovarian polycystic changes: ≥12 follicles on one or both sides with ovarian diameters of 2-9 mm, and (or) ovarian volume ≥10 mL. Two of the three criteria were met, and other causes for hyperandrogenism, such as congenital adrenal hyperplasia, Cushing’s syndrome and tumors with androgen secretion, were excluded.

Methods: The control group was started on orally taken metformin (Guizhou Tian’an Pharmaceutical Co., Ltd., National Medicine Permit No.H52020469) on the 1st-3rd days from menstruation or withdrawal bleeding, 500 mg/time, 3 times/day.4 It was taken after or at meal for three consecutive menstrual cycles. The patients began to additionally take clomiphene from the 5th day of the 4th menstrual cycle (Shanghai Hengshan Pharmaceutical Co., Ltd., National Medicine Permit No.H31021107), 50-100 mg/time, once/day. It was taken for 5 consecutive days and for 3 consecutive menstrual cycles.

The observation group received lifestyle adjustment on the basis of the control group:
Low-fat diet: Carbohydrates mainly included oats and ordinary Japanese rice, with oil intake limited and fat and fried foods avoided; proteins were mainly derived from plants, fish and shrimp.
Exercise strengthening: Exercise with unlimited forms was taken once (at least 30 min each time) in the morning and evening respectively and stopped when the patients began to sweat, which lasted for 6 consecutive months.
Smoking and drinking were forbidden, and the patients were followed up at regular intervals.

Observation indices:
The body weight, body mass index (BMI) and waist-to-hip ratio (WHR) were measured before and after treatment. BMI = Body mass (kg)/ (height (m))^2; WHR = waist circumference (cm)/hip circumference (cm).

Determination of reproductive hormones:
Fasting venous blood was drawn on the 3rd-5th days of the menstrual cycle or during the early follicular phase by B-ultrasonography. The levels of luteinizing hormone (LH), testosterone (T), follicle-stimulating hormone (FSH), fasting insulin (FINS) and triglyceride (TG) were measured by immunoassay. The kits with eligible inner- and inter-batch errors were all purchased from Bayer Diagnostics Ltd. (Hong Kong, China). The changes of ovaries and endometrium were detected by B-ultrasonography.
The menstrual recovery, ovulation and pregnancy rates of obese PCOS patients were observed six months after treatment.

Statistical analysis: All data were analyzed by SPSS18.0, and subjected to one-way analysis of variance and variance homogeneity test. In the case of homogeneous variance, the LSD method was combined with the SNK method. The categorical data were expressed as (χ² ±s) and compared by the t test. The numerical data were compared by the χ² test. P<0.05 was considered statistically significant.
RESULTS

Clinical therapeutic effects: There was no significant difference in WHR between the two groups. The body weight and BMI of the observation group after treatment were significantly lower than those before treatment and of the control group (P<0.05) (Table-I).

Changes in reproductive endocrine and lipid metabolism indices: In the observation group, there were significant differences in LH, T, LH/FSH, FINS and TG levels before and after treatment (P<0.05). The control group had significantly different LH, T and LH/FSH levels before and after treatment (P<0.05). After treatment, the two groups also had significantly different LH, T, LH/FSH, FINS and TG levels (P<0.05) (Table-II).

Changes in ovaries and endometrium: Both the left and right ovarian volumes of the observation group after treatment were significantly lower than those before treatment and of the control group after treatment (P<0.05) (Table-III).

Menstrual recovery, ovulation and pregnancy rates: The menstrual recovery, ovulation and pregnancy rates of the observation group significantly exceeded those of the control group (P<0.05) (Table-IV).

Adverse reactions: At the beginning of medication, both groups suffered from gastrointestinal reactions such as nausea, vomiting and abdominal discomfort that disappeared after two weeks. During the first course of treatment, three cases of the observation group had small amounts of vaginal bleeding which stopped spontaneously.

DISCUSSION

PCOS is the most common cause of menstrual disorders in women of reproductive age. The incidence of women in the reproductive period is about 5%-10%, but its etiology has not been fully clear yet.\(^5\) Endocrine disorders are the main clinical

---

**Table-I: Clinical therapeutic effects.**

| Group          | n   | Body weight (kg) | BMI (kg/m²) | WHR |
|----------------|-----|------------------|-------------|-----|
|                |     | Before treatment | After treatment | Before treatment | After treatment | Before treatment | After treatment |
| Observation    | 51  | 59.85±4.25       | 52.33±3.69 ▲ | 22.96±2.45 | 20.30±2.24 ▲ | 0.84±0.26       | 0.81±0.25       |
| Control        | 50  | 60.09±4.13       | 57.35±3.86  | 23.36±2.36 | 22.12±2.32  | 0.86±0.24       | 0.83±0.24       |
| t              |     | 0.689            | 7.557       | 0.691     | 4.403       | 0.359           | 0.625           |
| T              | >0.05| <0.05            | >0.05       | <0.05     | >0.05       | >0.05           |

*Note: ▲Compared with the data before treatment, P<0.05.*

**Table-II: Changes in reproductive endocrine and lipid metabolism indices.**

| Group          | LH (mIU/mL) | T (ng/mL) | LH/FSH | FINS (mIU/L) | TG (mmol/L) |
|----------------|-------------|-----------|---------|---------------|-------------|
|                | Observation (n=51) |     |         |               |             |
| Before treatment | 16.52±5.58 | 3.02±0.82 | 1.92±0.28 | 37.85±7.65 | 1.89±0.23 |
| After treatment | 6.58±1.35 ▲* | 0.95±0.13 ▲* | 1.23±0.18 ▲* | 20.21±4.30 ▲* | 1.47±0.23 ▲* |
| Control (n=50) | Before treatment | 16.70±5.48 | 3.03±0.78 | 1.95±0.30 | 38.14±7.42 | 2.06±0.32 |
| After treatment | 7.03±1.41 ▲ | 1.25±0.20 ▲ | 1.42±0.20 ▲ | 30.89±4.21 | 1.82±0.22 |

*Note: ▲Compared with the data of the same group before treatment, P<0.05; *Compared with control group after treatment, P<0.05.*

**Table-III: Changes in ovaries and endometrium.**

| Group          | n   | Left ovarian volume (mL) | Right ovarian volume (mL) | Endometrial thickness (mm) |
|----------------|-----|--------------------------|---------------------------|---------------------------|
|                |     | Before treatment | After treatment | Before treatment | After treatment | Before treatment | After treatment |
| Observation    | 51  | 8.56±2.56       | 5.63±1.25 ▲ | 8.32±2.62 | 5.45±1.09 ▲ | 6.79±2.60       | 6.35±2.39       |
| Control        | 50  | 8.63±2.48       | 6.72±1.34  | 8.29±2.58 | 7.08±1.32  | 6.72±2.45       | 6.34±2.43       |
| t              |     | 0.262           | 3.175       | 0.676     | 5.213      | 0.529           | 0.566           |
| P              | >0.05| <0.05            | >0.05       | <0.05     | >0.05      | >0.05           |

*Note: ▲Compared with the data of the same group before treatment, P<0.05.*
features of patients with PCOS, mainly manifested as increase of LH, LH/FSH and T at varying degrees, of which the reason may be the increased pituitary sensitivity to gonadotropin-releasing hormones, resulting in excessive LH secretion. Excessive LH can also stimulate theca cells and ovarian stroma to secret excessive androgen.6 Due to the above mechanisms, the ovarian androgen levels of PCOS patients were significantly higher than those of the normal women, and the follicle maturation process is inhibited, but the small follicles in the ovaries of patients can still secrete a certain amount of E2. At the same time, androstenedione can be transformed into estrone in peripheral tissues, and E2 and estrone can act on the hypothalamus and pituitary, whose positive feedback can lead to increased amplitude and frequency of LH secretion.

The patients are sustained with high levels of LH, with no cyclical changes, so PCOS patients have no occurrence of anovulation. In addition, about 50% of PCOS patients also have varying degrees of insulin resistance, with a very complex mechanism. The molecular mechanism is mainly related to multiple aspects such as pre-receptor, receptor-level and post-receptor insulin resistance.8 The excess insulin in PCOS patients can act on the pituitary insulin receptor, enhance the release of LH and promote the adrenal gland and ovarian androgen secretion, so as to further aggravate the patients’ condition.9

About 40%-60% of PCOS patients have symptoms of obesity that is more prone to hyperinsulinemia and insulin resistance, among which the three are closely linked with each other.9 Therefore, the lifestyle should be adjusted at first, and attention paid to diet and exercise to help patients lose weight, reduce the indicators of blood insulin, triglyceride and testosterone, increase sex hormone-binding globulin, which are all conducive to the ovulation and conception of obese PCOS patients and reduce the rate of abortion.10,11 Decrease in BMI plays a favorable role in pregnancy outcomes and the improvement of endocrine and metabolic disorders.12 In this study, there was no significant difference in WHR between the two groups before and after treatment (P>0.05).

Since metformin was used to treat PCOS for the first time in 1994, many clinical studies have been performed. As an insulin-sensitive drug, metformin improves glucose metabolisms by promoting glucose absorption in the intestinal tract, reducing abnormal production of hepatic glycogen, facilitating anaerobic glycolysis and increasing glucose uptake and utilization by peripheral tissues such as muscles. As a result, the sensitivity to insulin is augmented, and the blood sugar level is decreased, accompanied by improved WHR.14 Meanwhile, insulin resistance-induced compensatory hyperinsulinemia was mitigated. Decrease in insulin level lowers those of LH and androgen as well as LH/FSH, helps correct hirsutism and acne, and recovers ovulatory menstruation.15 Palomba et al.16 found that the cumulative ovulation rate using metformin was similar to that using clomiphene, but the former led to higher rates of pregnancy and live birth.

In the observation group of metformin and clomiphene combined with lifestyle adjustment (including low-fat diet, exercise strengthening and forbidding of smoking and drinking), the weight and BMI after treatment were significantly lower than those before treatment and of the control group (metformin and clomiphene only) after treatment, among which the differences were statistically significant (P<0.05). Thus, the combination of metformin and clomiphene with lifestyle adjustment evidently reduced body weight, BMI and WHR. In the observation group, there were significant differences in LH, T, LH/FSH, FINS and TG levels before and after treatment (P<0.05).

In the control group, the differences in LH, T and LH/FSH were all significant between before and after treatment (P<0.05). After treatment, the two groups also had significantly different LH, T, LH/FSH, FINS and TG levels (P<0.05). Both the left and right ovarian volumes of the observation group after treatment were significantly lower than those before treatment and of the control group after treatment, with the differences being statistically significant (P<0.05). The menstrual recovery rate, ovulation rate and pregnancy rate

| Table-IV: Menstrual recovery, ovulation and pregnancy rates. |
|-----------------------------------------------------------|
| **Group**       | **n** | **Menstrual recovery rate** | **Ovulation rate** | **Pregnancy rate** |
|-----------------|-------|----------------------------|-------------------|-------------------|
| Observation     | 51    | 48 (94.12)                 | 40 (78.43)        | 18 (35.29)        |
| Control         | 50    | 32 (64.00)                 | 25 (50.00)        | 6 (12.00)         |
| χ²             |       | 17.524                     | 15.128            |                   |
| P               | <0.05 | <0.05                      |                   |                   |
of the observation group were significantly higher than those of the control group (P<0.05). Hence, for PCOS patients, the combination of medication with lifestyle adjustment had better effects than absolute medicine therapy, which could reduce body weight, regulate endocrine and metabolic disorders, restore menstruation to normal and improve ovulation rate.

In summary, lifestyle adjustment combined with metformin and clomiphene can significantly relieve insulin sensitivity of infertile patients with PCOS, lower BMI, regulate endocrine and metabolic disorders, recover menstruation to normal and elevate ovulation rate, as an ideal method for the treatment of PCOS-induced infertility.

Source of funding: Health Department of Shanxi Province Foundation (No. 2015134).

REFERENCES

1. Ghazeeri G, Kutteh WH, Bryer-Ash M, Haas D, Ke RW. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril. 2003;79(3):562-566.
2. De Leo V, Musacchio MC, Palermo V, Di Sabatino A, Morgante G, Petraglia F. Polycystic ovary syndrome and metabolic comorbidities: therapeutic options. Drugs Today (Barc). 2009;45(10):763-775. doi: 10.1396674/dot.2009.45.10.1429463.
3. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25.
4. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, et al. Clomiphene, Metformin, or Both for Infertility in the Polycystic Ovary Syndrome. N Engl J Med. 2007;356(6):551-566.
5. Tan S, Hahn S, Benson S, Dietz T, Lahner H, Moeller LC, et al. Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. Eur J Endocrinol. 2007;157(5):669-676.
6. Fusco A, Bianchi A, Mancini A, Milardi D, Giampietro A, Cimino V, et al. Effects of ghrelin administration on endocrine and metabolic parameters in obese women with polycystic ovary syndrome. J Endocrinol Invest. 2007;30(11):948-956.
7. Yin Q, Fischer L, Noethling C, Schaefer WR. In vitro-assessment of putative antiprogesterin activities of phytochemicals and synthetic UV absorbers in human endometrial Ishikawa cells. Gynecol Endocrinol. 2015;31(7):578-581. doi: 10.3109/09513590.2015.1047448.
8. Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril. 2009;92(6):1966-1982. doi: 10.1016/j.fertnstert.2008.09.018.
9. Teede HJ, Meyer C, Hutchison SK, Zoungas S, McGrath BP, Moran LJ. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy. Fertil Steril. 2010;93(1):184-191. doi: 10.1016/j.fertnstert.2008.09.034.
10. He D, Jiang F. Meta-analysis of letrozole versus clomiphene citrate in polycystic ovary syndrome. Reprod Biomed Online. 2011;23(1):91-96. doi: 10.1016/j.rbmo.2011.03.024.
11. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab. 2000;85(9):3161-3168.
12. Machado RB, Tachetti F, Cavenague G, Maia E. Effects of two different oral contraceptives on total body water: a randomized study. Contraception. 2006;73(4):344-347.
13. Wang Y. Effect analysis of metformin combined with clomiphene in the treatment of polycystic ovarian syndrome combined with infertility. Chinese Community Doctors, 2014(21):78-80.
14. Li YQ, Ma Y, Song ZR, Pen J, Liao GF, Zhang Y. Clinical observation of marvelon combined with metformin in the treatment of 30 cases of pubertal polycystic ovary syndrome. Hainan Med J. 2012;23(15):76-78.
15. Motta DA. Metformin in the treatment of polycystic ovary syndrome. Curr Pharm Des. 2008;14(21):2121-2125.
16. Palomba S, Orio F Jr, Falbo A, Manguso F, Russo T, Cascella T, et al. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90(7):4068-4074.

Authors' Contribution:

JZ & QS conceived, designed and did statistical analysis & editing of manuscript.

QS & JL did data collection and manuscript writing.

JZ did review and final approval of manuscript.

JZ takes the responsibility and is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.